KIR2DL1 and plasma cell myeloma: In addition, Lirilumab, an anti-KIR blocking antibody that targets the inhibitory KIR2DL1, -2 and -3 receptors (and the activating receptors KIR2DS1 and -2) is also available and has shown limited side effects (46), but unfortunately also limited efficacy in the treatment of patients with hematologic malignancies (such as acute myeloid leukemia and myeloma) and some solid tumors.